Deals
Madrigal Pays $25M Up, Bets $1B on Arrowhead RNAi
Madrigal's $1B bet on Arrowhead's ARO-PNPLA3 targets a PNPLA3 mutation affecting 30% of MASH patients that Rezdiffra doesn't cover.
Deals — Page 2
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Amgen Adds $300M to Puerto Rico Biologics Site
Amgen drops another $300M into its Puerto Rico biologics site, bringing Juncos to nearly $1B total and U.S. manufacturing pledges close to $2B.
Deals
Bid $55.5B for eBay: GameStop Can't Cover It
GameStop offered $55.5B for eBay at $125 a share, a 46% premium, but CNBC's math found a $16 billion gap Ryan Cohen couldn't explain.
Deals
Windward Bio Raises $165M for Late-Stage Trial
Swiss biotech Windward Bio raised $165M to advance a China-derived drug into late-stage testing. What investors get from this bet is the real question.
Deals
Ken Song's T Cell Engager Bet Gets Picked Up
Ken Song has done it again.
Deals
Bought Candid for $2B, UCB Challenges Gilead on TCE
UCB bought Candid Therapeutics for $2 billion upfront, plus up to $200 million in development milestones, cutting off a planned reverse merger with…
Deals
Novartis Seals $23B US Build With NC API Plant
Novartis has committed $23 billion to build seven U.S. facilities, and the final piece just landed in Morrisville, North Carolina: a 56,200-square-foot…
Deals
Bought: Sun Pharma's $11.75B Organon Deal
Sun Pharma paid $11.75 billion for Organon, the largest biopharma acquisition of 2026 and the biggest deal any Indian drugmaker has ever announced.
Deals
BeOne Buys $2B Option on Huahui Trispecific
BeOne Medicines is paying $20 million upfront to reserve an exclusive option on HH160, a preclinical trispecific antibody from Beijing-based Huahui Health.
Deals
OppFi Buys Arizona Bank for $130M at 1.2x Book
OppFi paid $130 million for BNCCORP and its BNC National Bank subsidiary, a cash-and-stock deal that values the Glendale, Arizona lender at 1.2 times its…
Deals
Adyen Bought Talon.One for $876M
Adyen paid €750 million ($876 million) in cash to buy Talon.
Deals
Paid $1.9B: Chiesi Bought KalVista and Its Approved Drug
Chiesi paid roughly $1.9 billion to buy KalVista Pharmaceuticals, an Italian pharma adding a commercial-stage biotech to its portfolio.
Deals
AbbVie Buys $1.45B Option on Kestrel's KRAS Program
AbbVie has secured an exclusive right to buy Kestrel Therapeutics for up to $1.45 billion, with the biotech required to hit unspecified development and…
Deals
Sun Pharma Bought Organon for $11.75B, Debt Included
Sun Pharma paid $11.75 billion, or $14 a share in cash, to buy Organon in a deal that positions the India-based generics maker among the world's biosimilar…
Deals
Lilly Bought Ajax for $2.3B on a JAK2 Resistance Bet
Eli Lilly paid up to $2.3 billion for Ajax Therapeutics on April 27, adding a Phase 1 myelofibrosis asset to a deal streak that's included Verve ($1B…
Deals
Lilly Bought In Vivo CAR-T as Sanofi Faces Reckoning
Eli Lilly bought an in vivo CAR-T biotech, terms undisclosed.
Deals
Google Commits $40 Billion to Anthropic at $350 Billion Valuation
Google put $10 billion into Anthropic on Friday at a $350 billion valuation, with another $30 billion committed contingent on performance milestones.
Deals
Paid $9B for Clario, Thermo Fisher Raises 2026 Revenue Guidance
Thermo Fisher paid $9 billion for Clario and got $30 million back in Q1.
Deals
Kailera Raises Record $625M IPO on Hengrui GLP-1 Pipeline
Kailera Therapeutics raised $625 million in a record IPO for an obesity biotech.
Deals
Regeneron Closes MFN Deal, Completing 17-Company White House Sweep
Regeneron signed the White House's most-favored-nation drug pricing deal Thursday, becoming the 17th and final company to do so — closing out a sweep that…
